首页> 美国卫生研究院文献>Diabetes >Imatinib Mesylate Reduces Endoplasmic Reticulum Stress and Induces Remission of Diabetes in db/db Mice
【2h】

Imatinib Mesylate Reduces Endoplasmic Reticulum Stress and Induces Remission of Diabetes in db/db Mice

机译:甲磺酸伊马替尼降低db / db小鼠的内质网应激并诱导糖尿病缓解

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>OBJECTIVE—Imatinib has been reported to induce regression of type 2 diabetes in chronic leukemia patients. However, the mechanism of diabetes amelioration by imatinib is unknown, and it is uncertain whether imatinib has effects on type 2 diabetes itself without other confounding diseases like leukemia. We studied the effect of imatinib on diabetes in db/db mice and investigated possible mechanism's underlying improved glycemic control by imatinib.>RESEARCH DESIGN AND METHODS—Glucose tolerance and insulin tolerance tests were done after daily intraperitoneal injection of 25 mg/kg imatinib into db/db and C57BL/6 mice for 4 weeks. Insulin signaling and endoplasmic reticulum stress responses were studied by Western blotting. β-Cell mass and apoptotic β-cell number were determined by combined terminal deoxynucleotidyl transferase–mediated dUTP nick-end labeling (TUNEL) staining and insulin immunohistochemistry. The in vitro effect of imatinib was studied using HepG2 cells.>RESULTS—Imatinib induced remission of diabetes in db/db mice and amelioration of insulin resistance. Expression of endoplasmic reticulum stress markers in the liver and adipose tissues of db/db mice, such as phospho-PERK, phospho-eIF2α, TRB3, CHOP, and phospho–c-Jun NH2-terminal kinase, was reduced by imatinib. Insulin receptor substrate-1 tyrosine phosphorylation and Akt phosphorylation after insulin administration were improved by imatinib. Serum aminotransferase levels and hepatic triglyceride contents were decreased by imatinib. Pancreatic β-cell mass was increased by imatinib, accompanied by decreased TUNEL+ β-cell and increased BrdU+ β-cell numbers. Imatinib attenuated endoplasmic reticulum stress in hepatoma cells in vitro.>CONCLUSIONS—Imatinib ameliorated endoplasmic reticulum stress and induced remission of diabetes in db/db mice. Imatinib or related compounds could be used as therapeutic agents against type 2 diabetes and metabolic syndrome.
机译:>目的— 据报道,伊马替尼可诱导慢性白血病患者2型糖尿病的消退。但是,伊马替尼改善糖尿病的机制尚不清楚,尚不确定伊马替尼是否对2型糖尿病本身有影响,而不会引起其他混杂疾病如白血病。我们研究了伊马替尼对db / db小鼠糖尿病的作用,并研究了伊马替尼改善血糖控制的潜在机制。>研究设计和方法— 每天腹腔注射25次后进行葡萄糖耐量和胰岛素耐量测试mg / kg伊马替尼进入db / db和C57BL / 6小鼠,持续4周。通过蛋白质印迹研究了胰岛素信号传导和内质网应激反应。通过结合末端脱氧核苷酸转移酶介导的dUTP缺口末端标记(TUNEL)染色和胰岛素免疫组化测定β细胞的质量和凋亡的β细胞数量。使用HepG2细胞研究了伊马替尼的体外作用。>结果— 伊马替尼诱导db / db小鼠糖尿病的缓解和胰岛素抵抗的改善。伊马替尼降低了db / db小鼠肝脏和脂肪组织中内质网应激标志物的表达,例如磷酸化PERK,磷酸化eIF2α,TRB3,CHOP和磷酸化-c-Jun NH2末端激酶。伊马替尼可改善胰岛素给药后胰岛素受体底物1酪氨酸的磷酸化和Akt的磷酸化。伊马替尼可降低血清氨基转移酶水平和肝甘油三酯含量。伊马替尼可增加胰岛β细胞的数量,并伴有TUNEL + β细胞减少和BrdU + β细胞数量增加。伊马替尼可减轻体外肝癌细胞中内质网的应激。>结论— 伊马替尼改善了db / db小鼠的内质网应激并诱导了糖尿病的缓解。伊马替尼或相关化合物可用作抗2型糖尿病和代谢综合征的治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号